Suppr超能文献

全球临床试验中的数据完整性:美国食品药品监督管理局和英国药品及医疗保健产品监管局联合良好临床实践研讨会讨论内容

Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop.

作者信息

Khin Ni A, Francis Gail, Mulinde Jean, Grandinetti Cheryl, Skeete Rachel, Yu Bei, Ayalew Kassa, Cho Seongeun-Julia, Fisher Andrew, Kleppinger Cynthia, Ayala Ruben, Bonapace Charles, Dasgupta Arindam, Kronstein Phillip D, Vinter Stephen

机构信息

Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.

Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.

出版信息

Clin Pharmacol Ther. 2020 Nov;108(5):949-963. doi: 10.1002/cpt.1794. Epub 2020 Mar 28.

Abstract

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials. Regulatory agencies conduct GCP inspections to verify the integrity of data generated in clinical trials and to assure the protection of human research subjects, in addition to ensuring that clinical trials are conducted according to the applicable regulations. The first joint GCP workshop of the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA-UK) was held in October 2018 and provided the agencies' perspectives on the importance of data quality management practices on data integrity. Regulatory perspectives on data blinding to minimize introduction of bias, and the role of audit trails in assessing data integrity in global clinical trials were discussed. This paper summarizes considerations of both agencies on these topics, along with case examples.

摘要

《药物临床试验质量管理规范》(GCP)是一项用于设计、实施、记录和报告临床试验的国际伦理与科学质量标准。监管机构开展GCP检查,以核实临床试验所产生数据的完整性,并确保对人类研究受试者的保护,同时确保临床试验依据适用法规进行。美国食品药品监督管理局(FDA)药品评价和研究中心(CDER)与英国药品和医疗产品监管局(MHRA-UK)于2018年10月联合举办了首届GCP研讨会,会上介绍了两机构对于数据质量管理措施对数据完整性的重要性的观点。会议还讨论了监管机构对于使偏差最小化的数据盲法以及审计追踪在评估全球临床试验数据完整性中的作用的观点。本文总结了两机构在这些议题上的考量,并列举了案例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验